doi: 10.1016/j.physbeh.2022.113967 [DOI] [PubMed] [Google Scholar] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article
These results taken together suggest that adding even mild amounts of GR agonism (to increase energy expenditure) on top of a dual agonist like Tirzepatide is able to produce even more pronounced decreases in weight
There is a critical need for integrative research grounded in systems biology
Thus, it is possible that the low concentrations used here were insufficient for ER binding but sufficient to interact with ER and/or suppress esr2 transcription
a systemic collagen concern, the optimal doses differ
May 16, 2026- A new study from Veterans Affairs, published last month in JAMA Network Open, adds further weight to a growing body of evidence connecting GLP-1 medications to a heightened risk of non-arteritic anterior ischemic optic neuropathy, or NAION a condition in which damage to the optic nerve can cause symptoms ranging from mild vision disturbances to permanent blindness